Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.4.1 (
phosphodiesterase
)
18,767
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Acetylsalicylic acid (ASA) and three structurally related benzoic acid derivatives,
2-acetylbenzoic acid
(ABA), 3-methylphthalide (3-MP), and 3-hydroperoxy-3-methylphthalide (3-HMP), were tested for inhibitory effects on three human blood platelet cyclic nucleotide phosphodiesterase (
PDE
) activities. 3-MP caused a dose-dependent inhibition of the high and low affinity cyclic AMP
PDE
activities and the cyclic GMP
PDE
activity. 3-HMP had some inhibitory effects but only on the low affinity cyclic AMP
PDE
activity. ASA and ABA had no effects. This study shows that progressive structural changes in the ASA molecule can shift the pharmacological profile from a cyclooxygenase inhibitor (ASA) to an inactive compound (ABA) to a
PDE
inhibitor (3-MP) and back again to a cyclooxygenase inhibitor (3-HMP). It is proposed that the potent anti-inflammatory effects of 3-MP, which differ from those of ASA, are mediated through the inhibition of the cyclic nucleotide
PDE
system.
...
PMID:Cyclic nucleotide phosphodiesterase inhibition by a benzoic acid derivative. 242 Jan 62